Abbott announces the upcoming launch of NeuroSphere myPath, a digital health app designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.
Abbott to Launch the NeuroSphere myPath Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
Abbott today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation or dorsal root ganglion therapy. During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their …
Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well
Abbott Thursday announced the upcoming launch of NeuroSphere myPath, a digital health app designed to track patient-perceived pain relief and general well-being associated with spinal cord stimulation or dorsal root ganglion therapy.